Vismodegib

Hedgehog Pathway Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Vismodegib is an onp drug in the Hedgehog Pathway Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Smoothened Receptor Antagonists. DrugCentral lists 5 molecular targets, including Shh, Smo and SHH. Recorded indications include Basal cell carcinoma of skin.

• Approval status: onp (first approved 2012 by the FDA).
• Drug class: Hedgehog Pathway Inhibitor.
• Mechanism of action: Smoothened Receptor Antagonists.
• Molecular targets: Shh, Smo, SHH and SMO (5 listed in DrugCentral).
• Indications: Basal cell carcinoma of skin.
• ATC code: L01XJ01 (Hedgehog pathway inhibitors).
• Molecular formula: C19H14Cl2N2O3S; molecular weight 421.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Basal cell carcinoma of skin

Contraindications (3)

• Breastfeeding (mother)
• Hypericum perforatum extract
• Pregnancy, function

Mechanism & targets

• Mechanism of action (MoA): Smoothened Receptor Antagonists
• Established pharmacologic class: Hedgehog Pathway Inhibitor

Molecular targets (5)

Target	Gene	Action	Activity
Sonic hedgehog protein	Shh	unknown	IC50 8.52
Smoothened homolog	Smo	unknown	IC50 8.30
Sonic hedgehog protein	SHH	unknown	IC50 7.82
Smoothened homolog	SMO	inhibitor	Ki 7.79
ATP-binding cassette sub-family G member 2	ABCG2	unknown	IC50 5.85

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2013-07-12	EMA	—	Roche Registration Ltd
2012-01-30	FDA	—	GENENTECH

ATC classification

ATC code	Therapeutic hierarchy
L01XJ01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Hedgehog pathway inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Muscle spasms	1891.2
Ageusia	1225.7
Dysgeusia	1148.4
Alopecia	1008.4
Death	393.7
Weight decreased	391.2
Squamous cell carcinoma	297.7
No adverse event	260.5
Decreased appetite	253.9
Fatigue	121.1
Myalgia	91.4
Nausea	85.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vismodegib is on its molecule page.

• Molecular formula: C₁₉H₁₄Cl₂N₂O₃S
• Molecular weight: 421.29 g/mol
• CAS number: 879085-55-9
• InChIKey: BPQMGSKTAYIVFO-UHFFFAOYSA-N
• PubChem CID: 24776445

CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vismodegib used for?

DrugCentral lists the following indications for Vismodegib: Basal cell carcinoma of skin.

How does Vismodegib work?

Vismodegib is classified as Smoothened Receptor Antagonists; its molecular targets in DrugCentral include Shh, Smo, SHH and SMO (inhibitor).

When was Vismodegib first approved?

Vismodegib was first approved by the FDA in 2012.

What drug class does Vismodegib belong to?

Vismodegib is in the Hedgehog Pathway Inhibitor class.

What is the chemical formula of Vismodegib?

Vismodegib has the molecular formula C19H14Cl2N2O3S and a molecular weight of 421.29 g/mol.

Sources

• DrugCentral drug card 4227 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL473417 — compound record and bioactivity
• PubChem CID 24776445 — chemical identifiers
• DrugBank DB08828 — drug record
• FDA UNII 25X868M3DS — substance identity
• DailyMed: FDA labels for Vismodegib — current prescribing information (label search)
• UniProt Q15465 (SHH) — target protein
• UniProt Q99835 (SMO) — target protein
• UniProt Q9UNQ0 (ABCG2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.